Nav: Home

Thyroid cancer patients opting for non-intervention report lack of support

March 09, 2017

Patients who choose not to intervene after a diagnosis of thyroid cancer face a challenging path--one that is often defined by a sense of isolation and anxiety, according to a first-of-its-kind study by researchers from The Dartmouth Institute for Health Policy and Clinical Practice and the Veteran's Administration in White River Junction, Vermont.

As the concept of cancer overdiagnosis--the identification of cancers that are unlikely to progress or cause the patient any harm--becomes better understood by the public, a small but growing minority of patients diagnosed with thyroid cancer are deciding not to intervene. The researchers note that the overdiagnosis of thyroid cancer has particularly large health ramifications because by age 50, half of the population has at least one thyroid nodule, and by age 90, almost everyone does -- making the portion of the population with potential for thyroid cancer diagnosis (or overdiagnosis) very large.

In the study, recently published in JAMA Otolaryngology, the researchers interviewed 22 people between the ages of 21-75 (average age of 49) who had decided not to intervene, despite this practice not being widely accepted. Study participants' thyroid cancer findings were all identified incidental to other health care activities, such as CT scans of the neck or chest, or evaluations of generalized symptoms such as weight gain. None of the study participants were experiencing any symptoms as a result of the thyroid cancer finding.

Among the study's key findings:
  • All 22 study participants questioned the course of treatment recommended by their physicians, but ultimate outcomes varied: 1 person had their cancer diagnosis reversed on obtaining a second opinion; 3 people ultimately decided to intervene. Reasons for non-intervention varied, with some participants quoting medical literature and published risk probabilities.

  • Participants reported that their decision not to intervene received little support or reassurance from health care providers and others, and 12 (of the 18) participants reported receiving skeptical, even derisive responses, such as being told they were "stupid," "wrong," or "crazy."

  • A large majority (15) of participants said they kept their thyroid cancer findings secret in order to avoid or manage this type of negative feedback, because as one person said, "untreated cancer is a scarlet letter."

  • Fourteen participants expressed a desire to hear about others' experiences of nonintervention or to connect with others going through a similar experience, yet only 3 individuals reported finding satisfactory support.

  • As a result of participants overall experiences, 5 of the 18 had discontinued surveillance, the recommended alternative to intervention.

  • Despite the challenges of choosing and living with non-intervention, 6 participants reported feeling glad they knew about their thyroid cancer finding; 4 were ambivalent, only7 wished they did not know.


The researchers note that while their study focuses on individuals "who face the challenge of living with their cancers, overdiagnosis is also a challenge for doctors who must live with the uncertainty of potentially missing a case they might have been able to manage earlier."

"Culturally we are conditioned to think that if you're diagnosed with cancer, you have to do everything you can to rid your body of that cancer. Changing attitudes toward non-intervention is likely to require a change in our larger social and media culture," said senior author Louise Davies, MD, MS, associate professor at The Dartmouth Institute and Chief of Otolaryngology at Veterans Administration in White River Junction, Vermont.

In the meantime, Davies and her co-authors note that early adopters of non-intervention for thyroid cancer would likely benefit from increased social and health system support, including educational programs. Studies in other cancers such as prostate cancer, which have been known to have incidence of overdiagnosis, have shown that those who receive such support are more likely to continue monitoring their cancers.
-end-
For full study: http://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2607926

The Dartmouth Institute for Health Policy & Clinical Practice

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...